Profile data is unavailable for this security.
About the company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-199.92m
- Incorporated1994
- Employees198.00
- LocationOmeros Corp201 Elliott Avenue WestSEATTLE 98119United StatesUSA
- Phone+1 (206) 676-5000
- Fax+1 (206) 676-5005
- Websitehttps://www.omeros.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onkure Therapeutics Inc | 0.00 | -41.03m | 234.11m | 8.00 | -- | 0.7928 | -- | -- | -12.25 | -12.25 | 0.00 | 22.14 | 0.00 | -- | -- | 0.00 | -39.45 | -- | -42.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 235.98m | 25.00 | -- | 3.93 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| 2Seventy Bio Inc | 44.12m | -156.25m | 236.89m | 274.00 | -- | 1.01 | -- | 5.37 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 237.20m | 17.00 | 3.70 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 238.60m | 112.00 | -- | 0.7154 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Nkarta Inc | 0.00 | -110.61m | 239.19m | 159.00 | -- | 0.5552 | -- | -- | -1.87 | -1.87 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -23.59 | -32.39 | -24.86 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 239.33m | 88.00 | -- | 1.40 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Omeros Corp | 0.00 | -199.92m | 248.59m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Nektar Therapeutics | 93.16m | -177.08m | 252.19m | 137.00 | -- | 3.16 | -- | 2.71 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 252.64m | 158.00 | -- | 0.8984 | -- | 22.02 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -69.00m | 254.90m | 58.00 | -- | 1.18 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 256.96m | 59.00 | -- | 3.10 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.24m | 261.42m | 32.00 | -- | 1.79 | -- | 307.55 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 262.84m | 58.00 | -- | 1.59 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Omeros Corp's reporting currency: US Dollar USD
33.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ingalls & Snyder LLCas of 30 Jun 2024 | 4.59m | 7.93% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.75m | 6.47% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.14m | 5.43% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Jun 2024 | 1.90m | 3.28% |
| D. E. Shaw & Co. LPas of 30 Jun 2024 | 1.58m | 2.72% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.33m | 2.30% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.22m | 2.11% |
| Corient Private Wealth LLCas of 30 Jun 2024 | 726.45k | 1.25% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 563.10k | 0.97% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 512.81k | 0.89% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
